23andMe Holding Co. logo
23andMe Holding Co. (ME)
Compare

23andMe Holding Co. (ME) Average EV/Sales Ratio

EV/Sales Ratio

The current ev/sales ratio for 23andMe Holding Co. (ME) is N/A as of Monday, June 15, 2026, shown against its trailing averages.

Average EV/Sales Ratio Chart

ME EV/Sales Ratio Averages

EV/SALES RATIO CURRENT

N/A

EV/SALES RATIO TTM

0.35x

EV/SALES RATIO 3Y

0.71x

EV/SALES RATIO 5Y

3.53x

EV/SALES RATIO 10Y

3.53x

EV/SALES RATIO 15Y

3.53x

EV/SALES RATIO 20Y

3.53x

About 23andMe Holding Co.

23andMe Holding Co. is a prominent direct-to-consumer genetic testing firm, structured around two primary business units: Consumer & Research Services and Therapeutics. Through its Consumer & Research Services division, the company provides individuals with a comprehensive suite of genetic reports, derived from a simple saliva sample collected via their proprietary kit. These reports offer insights into customers' genetic ancestral origins, predispositions to certain personal health risks, the likelihood of being a carrier for rare conditions that could be passed to offspring, and how their genetic makeup might influence responses to various medications. The Therapeutics segment is dedicated to pharmaceutical research and development, focusing on the discovery and advancement of novel treatments aimed at improving patient well-being across diverse medical fields, including oncology, respiratory, and cardiovascular diseases. This segment also engages in the out-licensing of intellectual property associated with identified drug targets that are progressing through clinical development. 23andMe maintains a strategic partnership with GlaxoSmithKline Intellectual Property (No.3) Limited, leveraging genetic insights to validate, develop, and ultimately commercialize new pharmaceutical products. Established in 2006, the company's corporate headquarters are situated in South San Francisco, California.

South San Francisco, CA
560 employees
Healthcare / Medical - Diagnostics & Research
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Joseph Selsavage